Prognostic Performance of Pretreatment Systemic Immune-Inflammation Index in Women with Epithelial Ovarian Cancer

Abstract

Purpose: This study investigated the prognostic performance of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC) in Lagos, Nigeria. Methods: We performed a secondary analysis of the data of 91 women who had treatment for EOC between 2009 and 2018. The associations between pretreatment SII and survivals were tested. Results: Pretreatment SII more than 610.2 was a significant independent predictor of reduced progression-free survival (HR = 2.68; 95% CI, 1.17 to 6.09) while SII greater than 649.0 was a significant independent predictor of reduced 3-year overall survival (HR = 2.01; 95% CI, 1.01 to 3.99). Conclusion: These findings suggest that high SII may be a potential prognostic indicator and useful marker for more intensive surveillance and design of personalized treatment in patients with EOC.

Prognostic Significance of Preoperative Inflammation Markers on the Long-Term Outcomes in Peritoneal Carcinomatosis from Ovarian Cancer

“…In this respect, investigators worldwide came to demonstrate that a higher number of platelets associated with a higher number of circulating neutrophils and monocytes and a lower level of lymphocytes significantly influenced the long-term outcomes of ovarian cancer. Moreover, this correlation proved to be present even when studying the influence of certain ratios such as the platelet-to-lymphocyte ratio, lymphocyteto-monocyte ratio, neutrophil-to-lymphocyte ratio [20][21][22][23][24][25].…”

“…Moreover, Wang et al underlined the fact that dynamic modifications of SII at six weeks postoperatively in patients with hepatocarcinoma had a predictive value in identifying cases with improved prognosis after resection [28]. Meanwhile, it seems that this parameter is useful for estimating the extent of the disease in peritoneal carcinomatosis from ovarian or colorectal origin [20][21][22][23][24][25] as well as the therapeutic response at chemotherapy alone or in association with monoclonal antibodies. Therefore, a recent study conducted on patients with peritoneal carcinomatosis from ovarian cancer demonstrated that patients presenting a pretreatment value of SII over 730 did not benefit after adjusting bevacizumab to standard chemotherapy alone while cases presenting a lower value of this parameter reported a significantly improved outcome after bevacizumab association [29].…”